RxDoctor Payments Data

Philip Gibbs, MD

Internal Medicine · Aberdeen, WANPI 1548283617

Payments from drug & device makers

$3,471in general payments, 2019–2025

Across 174 payments — averaging $19.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$745
  • Johnson & Johnson$463
  • Novartis$382
  • Pfizer$250
  • Amgen$247
  • Boehringer Ingelheim$159
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,35297%
  • Education$1203%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,471 in reported general payments places this provider in the 90th percentile of 2,038 internal medicine providers in Washington.

See all internal medicine providers in Washington

Medicare billing

Part B allowed, 2024
$438,244
Medicare patients
449
Services billed
7,227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban471$323,467
XareltoRivaroxaban118$88,289
Taltz AutoinjectorIxekizumab12$77,586
FarxigaDapagliflozin Propanediol67$65,295
JanuviaSitagliptin Phosphate76$62,270
TrulicityDulaglutide45$49,315
MounjaroTirzepatide35$36,514
OzempicSemaglutide21$31,268
Humalog Kwikpen U-200Insulin Lispro12$18,850
JardianceEmpagliflozin27$17,917
Combivent RespimatIpratropium/Albuterol Sulfate32$15,953
EntrestoSacubitril/Valsartan22$14,335
Atrovent HfaIpratropium Bromide19$13,555
Breo ElliptaFluticasone/Vilanterol24$12,438
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$10,845

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$250$323,467471 claims
Johnson & JohnsonXarelto$463$88,289118 claims
AstraZenecaFarxiga, Brilinta$745$73,57588 claims
MerckJanuvia, Janumet$61$71,322102 claims
Boehringer IngelheimJardiance, Combivent Respimat$159$33,87159 claims
NovartisEntresto$382$14,33522 claims
BayerKerendia$149$6,59611 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$21$5,17611 claims
Esperion Therapeutics, Inc.Nexlizet$59$3,96811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,038 internal medicine providers in Washington.

Other internal medicine in Aberdeen

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →